

Mouse Anti-VEGF/VEGFA [VG1]: MC0110, MC0110RTU7

Intended Use: For Research Use Only

Description: VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor in vivo because the expression pattern of VEGF is consistent with a role in embryonic angiogenesis. VEGF mRNA is formed in some primary tumors, VEGF is produced by tumor cell lines in vitro and VEGF mitogenic activity appears to be restricted to endothelial cells. A member of the PDGF receptor family, Flt, has been identified as a high-affinity receptor for VEGF. This clone recognizes proteins of 19-22 kDa (reducing) and 38-44 kDa (non-reducing), identified as various isoforms of VEGF or Vascular Permeability Factor (VEGF/VPF). This antibody recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF).

Specifications


Clone:	VG1
Source:	Mouse
Isotype:	IgG1k
Reactivity:	Human
Immunogen:	Human VEGF189 recombinant protein
Localization:	Cytoplasm, membrane, secreted
Formulation:	Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN ₃)
Storage:	Store at 2°- 8°C
Applications:	IHC, ELISA
Package:	

Description	Catalog No.	Size
VEGF/VEGFA Concentrated	MC0110	1 ml
VEGF/VEGFA Prediluted	MC0110RTU7	7 ml

IHC Procedure

Positive Control Tissue:	Tumor cells in astrocytomas, breast or ovarian carcinomas
Concentrated Dilution:	50-200
Pretreatment:	Tris EDTA pH9.0, 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human tonsil stained with anti-VEGF using DAB

References:

1. TRIIODOTHYRONINE ATTENUATES PROSTATE CANCER PROGRESSION MEDIATED BY β -ADRENERGIC STIMULATION. Delgado-González, E. et al. Mol. Med. 2016.
2. Differential expression of multidrug resistance-related proteins in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines. Zhao, M. et al. Mol Med Rep. 14: 4741-4746, 2016.